热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE/Cyanine7 anti-human CD279 (PD-1) Antibody
产品名称：
PE/Cyanine7 anti-human CD279 (PD-1) Antibody
产品类别：
抗体
产品编号：
329917
产品应用：
329917
[价格]
规格 价格 库存
25tests ￥ 2112 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3,?immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
  16. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
Product Citations
  1. Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed
  2. Zhou J, et al. 2020. Oncol Lett. 1.336111111. PubMed
  3. Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed
  4. Amancha P, et al. 2013. J Immunol. 191:6060. PubMed
  5. Hong J, et al. 2012. J Immunol. 188:3247. PubMed
  6. Policicchio B, et al. 2016. PLoS Pathog. 12: 1005879. PubMed
  7. Yoshitomi H, et al. 2018. Nat Commun. 2.9875. PubMed
  8. Wildner NH, et al. 2022. Front Immunol. 13:886646. PubMed
  9. Olwenyi OA, et al. 2020. Cells. 9:. PubMed
  10. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  11. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  12. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  13. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  14. Au L, et al. 2021. Cancer Cell. 39:1497. PubMed
  15. Hong J, et al. 2014. J Immunol. 193:797. PubMed
  16. Colleen S McGary et al. 2017. Immunity. 47(4):776-788 . PubMed
  17. Verma A, et al. 2021. Cell Rep. 37:109942. PubMed
  18. Tardif V, et al. 2019. Nat Commun. 10:823. PubMed
  19. Dart SJ, et al. 2021. Sci Rep. 11:15312. PubMed
  20. Khanam A, et al. 2021. Front Immunol. 11:599648. PubMed
  21. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  22. Hsu H, et al. 2016. J Immunol. 197: 1884 - 1892. PubMed
  23. Lee J, et al. 2020. Sci Rep. 10:17753. PubMed
  24. Punik J, et al. 2021. Cell Reports. 35(13):109320. PubMed
  25. Kuo HH, et al. 2018. Immunity. 48:1183. PubMed
  26. Ohue Y, et al. 2014. Clin Cancer Res. 20:5052. PubMed
  27. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  28. Gordon-Alonso M,et al. 2017. Nat. Commun. 10.1038/s41467-017-00925-6. PubMed
  29. Parsons E, et al. 2016. PLoS One. 11:e0167841. PubMed
  30. Shen C, et al. 2021. Front Immunol. 12:680055. PubMed
  31. Beltra JC, et al. 2020. Immunity. 52(5):825-841. PubMed
  32. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  33. Den Braanker H, et al. 2021. Front Immunol. 12:768113. PubMed
  34. Barili V, et al. 2020. Nat Commun. 0.877777778. PubMed
  35. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  36. Dehmani S, et al. 2021. Front Immunol. 12:732530. PubMed
  37. Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed
  38. Chen Y, et al. 2020. Cell. 1496:183. PubMed
  39. Brudno JN, et al. 2020. Nat Med. 270:26. PubMed
  40. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  41. Lederer K, et al. 2022. Cell. . PubMed
  42. Chellappa S, et al. 2019. J Immunol. 202:1397. PubMed
  43. Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed
  44. Rnjak D, et al. 2021. Transfus Clin Biol. . PubMed
  45. Csomós K, et al. 2022. Nat Immunol. 23:1256. PubMed
  46. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  47. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
  48. Hu JQ, et al. 2020. J Cancer. 3.409722222. PubMed
  49. Tang X, et al. 2020. Sci Adv. 6:eaaz0374. PubMed
RRID
AB_2159325 (BioLegend Cat. No. 329917) AB_2159324 (BioLegend Cat. No. 329918)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线